ClinicalTrials.gg
Active, not recruitingNCT02153229MPM-PDTUpdated Dec 26, 2025

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

A Phase 2 interventional study of Photodynamic Therapy and Radical Pleurectomy in Epitheliod Malignant Pleural Mesothelioma, sponsored by Abramson Cancer Center at Penn Medicine. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Abramson Cancer Center at Penn Medicine · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Mesothelioma, Malignant with a site in United States — 21 open to participants now, 38 under way, 1 of them phase 3. Mesothelioma, Malignant · United States.

Enrollment
55th of 145
52 · median 33
Started
2014
with 1 other
Phase 2
60 of 165
6 open now
Primary completion
2026-12
later than 8 of 36 live
Registered
85th of 165
by date
Lead sponsor
5 of 165
Abramson Cancer Center at Penn Medicine

Among the 165 studies in Mesothelioma, Malignant with a site in United States, this one is the 55th largest by enrollment of the 145 interventional ones that give a count, is one of 2 that started in 2014, is one of 60 in phase 2, reaches primary completion later than 8 of the 36 other live ones, and was the 85th registered.

Mesothelioma, Malignant

340 studies on the registry are indexed under Mesothelioma, Malignant; 63 are open to participants now.

Browse Mesothelioma, Malignant studies →

Open to participants now

21 of the 165 studies in Mesothelioma, Malignant with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Mesothelioma, Malignant studies recruiting now, 42 (78%) set no upper age limit and 5 (9%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Mesothelioma, Malignant with a site in United States, or all of them as a file.
02

Study summary

A randomized Phase II trial to test whether the addition of intraoperative Photofrin-mediated photodynamic therapy to radical pleurectomy and post-operative chemo.improves OS in the treatment of patients with epithelioid MPM. Subjects assigned to the PDT arm will be given the photosensitizer prior to surgery . All subjects will receive maximal surgical debulking. Subjects in the PDT arm will receive intraoperative treatment using real-time, isotropic light dosimetry.

03

Conditions studied

  • Epitheliod Malignant Pleural Mesothelioma

Keywords

  • Histological diagnosis of MPM
  • epitheliod subtype
  • limited to the hemithorax
  • macroscopically complete resection of the tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a histologic diagnosis of MPM, epithelioid subtype, who in the opinion of the attending thoracic surgeon can receive a macroscopically complete resection of tumor.
  • Patients must have disease limited to the hemithorax.
  • Patients who have received prior surgery, gene therapy, or combination chemotherapy will be permitted if it has been at least 30 days since the last treatment.
  • Subjects treated with pemetrexed previously will be eligible only if 30 days have elapsed between the last dose of pemetrexed and the date of surgery.
  • performance status of 0-1.
  • Medical suitability for resection, including documented medical and cardiac clearance.
  • 18 years of age or older.
  • Patients must sign a document that indicates that they are aware of the investigative nature of the treatment of this protocol, and the potential benefits and risks. Patients unwilling or unable due to cognitive impairment to sign are excluded from the study.

Exclusion criteria

EXCLUSION CRITERIA

  • Patients with active invasive cancers, other than MPM, that require additional treatment, except non-melanomatous skin cancer, superficial bladder or cervical cancer, and early-stage prostate cancer
  • Pregnant or lactating patients.
  • Patients who have a history of disease.
  • Patients who have a white count less than 2,500 per cubic mm or less than 100,000/cubic mm.
  • Serum creatinine equal or greater than 2.5 mg/deciliter.
  • Patients who have severe liver disease including cirrhosis, Grade III-IV elevations in liver function studies, or in excess of 1.5 mg/deciliter.
  • Patients with porphyria or to porphyrin or porphyrin-like compounds.
  • Patients who have been treated with pemetrexed if the last dose of pemetrexed is \< 30 days to the date of surgery.
  • Patients that have been treated with prior Mantle field radiation.
  • Patients with distant disease or otherwise not confined to the ipsilateral hemithorax.
  • Subjects who have received more than 2 doses of chemotherapy
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    patients who undergo RP plus photofrin-based PDT

    Radiation: Photodynamic Therapy · Procedure: Radical Pleurectomy · Radiation: Chemotherapy · Drug: Photofrin 2.0 mg/kg

  • Experimental
    patients who undergo RP alone

    Procedure: Radical Pleurectomy · Radiation: Chemotherapy

Interventions

  • RadiationPhotodynamic Therapy

    Also known as: PDT

  • ProcedureRadical Pleurectomy

    Also known as: RP

  • RadiationChemotherapy
  • DrugPhotofrin 2.0 mg/kg

    Drug page: Dihematoporphyrin EtherStudies of Dihematoporphyrin EtherDihematoporphyrin Ether pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy

06

What researchers measure

Primary outcomes

  1. Survival months

    Time frame: 4 years

Secondary outcomes

  1. Progression-free survival months

    Time frame: 4 years

  2. Local Control

    progression with death as a competing risk

    Time frame: 4 years

  3. Receipt of Pembrolizumab

    Time frame: 4 years

07

Study locations

2 sites
08

References and documents

Publications

  • Sun H, Kim MM, Ong YH, Dimofte A, Singhal S, Busch TM, Cengel KA, Zhu TC. Comprehensive reanalysis of light fluence distribution in pleural photodynamic therapy using standardized anatomical coordinates. Photochem Photobiol. 2025 Sep-Oct;101(5):1165-1176. doi: 10.1111/php.14063. Epub 2025 Jan 21. PubMed 39838651 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2014 (actual). Primary completion is estimated for Dec 2026, 150 months after the start.

Of 41 non-industry phase 2 interventional studies under Mesothelioma, Malignant, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 100. This study's planned 150 months is above that.

Counting every sponsor, half of 48 studies reached it within 48 months; a quarter within 29 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2014
First posted
Jun 3, 2014
StartActual
Jun 2, 2014
Primary completionEst.
Dec 16, 2026
CompletionEst.
Dec 2027
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02153229
Responsible party
Sponsor
First posted
Jun 3, 2014
Start date
Jun 2, 2014
Primary completion
Dec 16, 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Dec 26, 2025

Study contacts

Keith Cengel, MD, PhD
principal investigator · Abramson Cancer Center at Penn Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dihematoporphyrin Ether

Start the discussion